Publication: Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients
Issued Date
2018-10-01
Resource Type
ISSN
13652710
02694727
02694727
Other identifier(s)
2-s2.0-85044393627
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Clinical Pharmacy and Therapeutics. Vol.43, No.5 (2018), 647-655
Suggested Citation
N. Kaewboonlert, W. Thitisopee, W. Sirintronsopon, S. Porntadavity, N. Jeenduang Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients. Journal of Clinical Pharmacy and Therapeutics. Vol.43, No.5 (2018), 647-655. doi:10.1111/jcpt.12682 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/46295
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients
Other Contributor(s)
Abstract
© 2018 John Wiley & Sons Ltd What is known: SLCO1B1 polymorphisms have been reported to affect the responses to statin therapy. However, the association of these polymorphisms and lipid-lowering responses has been inconsistent. Objective: To investigate the effect of SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms on the lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients. Methods: Three hundred and 91 hypercholesterolaemic patients in Southern Thailand were enrolled and treated with simvastatin 20 or 40 mg per day. Among them, 191 and 200 patients were treated for 3 and 12 months, respectively. Serum lipids were measured before and after the treatment. SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms were analysed using polymerase chain reaction-high-resolution melting (PCR-HRM). Results: The allele frequencies of the SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms in Thai hypercholesterolaemic patients were 74.9%, 11.8% and 37.2%, respectively. After treatment with 20-40 mg simvastatin daily for 3 and 12 months, TC, TG and LDL-C concentrations were significantly lower than at baseline (P <.05). However, there was no a significant change in serum HDL-C after simvastatin treatment for 3 and 12 months (P >.05). Moreover, there was no association between SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms and lipid-lowering response to 3 and 12 months of either 20 or 40 mg/day simvastatin treatment. What is new and conclusion: SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms may not be useful as genetic markers of lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients.